Ranitidine hydrochloride being one of the most commonly used drugs and its use is well provident. Furthermore, anaphylactic reactions are rarely observed with the use of ranitidine hydrochloride. Hypersensitivity reactions are usually common in clinical practice but adverse reaction to intravenous ranitidine is very rare. Here we report a case, where the patient developed an anaphylactic reaction with a single dose of intravenous ranitidine in cholangiocarcinoma patient. This report highlights the importance of recognition of the serious adverse events that might follow and the need for cautiousness with the use of ranitidine in the future prospects.
INTRODUCTION
Ranitidine is a competitive, reversible inhibitor of h 2 -receptors, prominently including the receptors on the gastric cells 1 thus characterized as Histamine H 2 -receptor antagonists, also known as H 2 blockers. Widely used over-the-counter (OTC), these medicines are used to relieve and/or prevent heartburn, acid indigestion, and sour stomach, and also as in prescription therapy for duodenal ulcers and in gastritis as a surface protectant. H 2 -blockers work by decreasing the amount of acid produced by the stomach. 2 The term wheal and flare reaction signifies a skin eruption that may follow injury or injection of an antigen, 2 characterized by swelling and redness caused by the release of histamine. The reaction usually occurs in three stages, beginning with the appearance of an erythematous area at the site of injury, followed by development of a flare surrounding the site and finally formation of wheals at the site as a result of fluid leakage under the skin from the surrounding capillaries. The incidence of wheal and flare reaction to ranitidine hydrochloride has been reported in all age groups. 3
CASE REPORT
A 67-year-old male was admitted in the intensive care unit of the public secondary care hospital, Udhagamandalam with complaints of hematemesis, abdominal pain, abdominal discomfort, swelling of both legs (peripheral edema), loss of appetite and jaundice and pain in the right shoulder.
T h e p a t i e n t i s a k n ow n c a s e o f cholangiocarcinoma with Liver and Spine Metastases. His CT Abdomen and Pelvis shows following:
• Large mass lesion involving segment II, III and IV of liver showing peripheral arterial enhancement with central progression in venous phase with delayed enhancement.
• Capsular retraction and left lobe atrophy.
• Minimal Intra hepatic biliary radicles dilatation.
• Invasion of left and middle hepatic veins.
• Multiple Intra hepatic metastatic lesions.
• Few enlarged lymph nodes in helium.
• Gall bladder and bowel appear normal.
• No metastatic lesion in bone or visualised portion of lung.
Features suggested of intrahepatic cholangiocarcinoma with multiple hepatic metastasis.
• Porto-systemic collaterals are seen around rectum. On examination, he was found to be conscious, oriented and afebrile. Pulse rate was 88 beats/min, blood pressure: 90/70 mmHg, oxygen saturation of 95% by pulse oximetry, whereas P/A shows the presence of hepatomegaly and ascites. Table 1 shows the laboratory data of the patient at the time of administration.
The Patient underwent trucut biopsy of liver and the results shows that multiple sections of tiny clusters of malignant epithelial cells with hyperchromatic nuclear cytoplasmic ratio forming tiny acini in a dense stroma, metastatic adenocarcinomatous deposits and cholangiocarcinoma.
The patient was prescribed with intravenous Ranitidine 50mg bid, Injection Tramadol 100mg IV bid, Injection Vitamin K 10mg/ml IM OD. Within min of the administration of injection ranitidine, the patient developed manifestations of itching, wheal and flare reaction on his forearm (Figure 1 ). After which, Ranitidine was stopped immediately and Tab. Cetirizine 5mg was prescribed to the patient.
Based on the above findings, he was diagnosed as a case exhibiting an adverse drug reaction due to intravenous ranitidine. Injection was stopped immediately and his vitals were normalised after stopping injection Ranitidine. On the next day poor prognosis of the patient was explained to the patient and his caretaker. Due to the poor prognosis, the patient was later referred to tertiary care hospital for further management. The event was 
DISCUSSION
Ranitidine is one of the most widely used drug and is considered rationally safe by most of the prescribers and the consumers. Highly attributing to its low incidence of adverse reactions. 4 Histamine plays an important role as a mediator of allergic reactions. It is stored in the granules of mast cells and basophils and is released not only when an allergen cross-links surface bound IgE, but also mediated by the complement system and other chemical or physical stimuli. 5 Ranitidine was introduced in 1981 and was the world`s biggest-selling prescription by 1987. It has since largely been superseded by the even more effective protonpump inhibitors, with omeprazole becoming the biggestselling drug for many years. Anaphylaxis is rarely seen with ranitidine. 6 A wide array of ranitidine-associated side effects has been reported but infrequently. 7 H 2 receptor antagonists are commonly used and prescribed medications and generally known to be well tolerated. 8 Literature reveals that this rare drug reaction occurs mostly with intravenous Ranitidine. The only way to prevent such type of adverse reaction is to evade the drugs for which the patient is found to be allergic. 9 The use of drug allergy card plays an important role for the safer design of a patient's therapy planning. Hypersensitivity to specific drugs by means of drug allergy card or by an electronic media 10 can contribute as a preventive measure. By such means, simultaneously the pharmacists can educate the patients and patient's relatives about anaphylactic reactions and their consequences to the overall wellbeing of the patient. A skin prick test with ranitidine is a good measure that requires more importance and more light in the present scenario of such circumstances. 11, 12 As a whole, though it has been considered safe notably because of the fewer reports of adverse effects. However, the need still arises with the high incidence of its use and the possibility of adverse reactions in some patients that might lead to critical conditions.
CONCLUSION
Ranitidine is most commonly used in the treatment for gastric ulcer and gastroesophageal reflux diseases. The incidence rate of adverse reactions associated with Ranitidine has been low, probably due to the less number of such events and such that cases may also be under reported. This case report emphasizes the need of caution and the probability that such events might follow with the use of Ranitidine. Furthermore, the need of reporting of such events to implement monitoring strategies and management approaches in the near future. Hypersensitivity drug reactions can be life-threatening, prolong hospital stay and hence further results in socioeconomic costs. 
